Search Results

Site Search

Updated assay guides diagnosis of autoimmune liver disease: Anne Tebo, Ph.D. - Insights

Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' updated ALDG2 assay helps with the evaluation of patients with suspected autoimmune liver disease. The panel also helps with the evaluation of liver disease of unknown etiology.

Panel offers proactive drug monitoring for IBD: Maria Willrich, Ph.D., and Melissa Snyder, Ph.D. - Insights

Maria Willrich, Ph.D., and Melissa Snyder, Ph.D., describe Mayo Clinic Laboratories' panel for proactive therapeutic drug monitoring of patients with inflammatory bowel disease. The panel expands options for clinicians assessing patients'...

MAG Antibody Testing [Test in Focus] - Insights

John Mills, Ph.D., explains Mayo Clinic Laboratories’ approach to MAG antibody testing. The ELISA-based assay uses higher reference ranges and human MAG antigen to detect MAG antibodies, which are associated with a rare, hard-to-treat...

T-cell lymphoma - Insights

We offer next-generation sequencing and comprehensive fluorescence in situ hybridization (FISH) panels, as well as extensive immunohistochemistry (IHC) offerings, to diagnose and monitor T-cell lymphoma.

Pan cancer - Insights

Learn about our comprehensive MayoComplete solid tumor panel, which analyzes 515 genes for mutations, rearrangements, and amplifications.

Lung Cancer NGS Panel - Mayo Clinic Laboratories

Our targeted lung cancer panel assesses for mutations in eight genes, and rearrangements in four genes, including those recommended by the National Comprehensive Cancer Network: EGFR, ROS1, BRAF, and ALK.

MayoComplete - Insights

Browse our menu of MayoComplete next-generation sequencing assays which are designed to identify a growing list of hematological cancers.

FISH testing - Insights

Find out how our streamlined approach to fluorescence in situ hybridization testing can simplify the ordering process and better meet patient needs.

Thrombotic microangiopathy (TMA) - Insights

View our comprehensive testing suite designed to confirm diagnosis and facilitate treatment of thrombotic microangiopathy.

Lipid assay improves cardiovascular risk prediction: Jeff Meeusen, Ph.D. - Insights

Jeff Meeusen, Ph.D., explains how Mayo Clinic Laboratories' new MI-Heart Ceramides assay helps guide the management of patients with mildly to moderately high cholesterol. The test measures levels of lipids beyond cholesterol that boost...